Latest News and Press Releases
Want to stay updated on the latest news?
-
Akuisisi Eczacıbaşı-Monrol yang diusulkan akan: Meningkatkan kemitraan yang sudah ada untuk Lu-177 yang membentuk produsen isotop terkemukaMenambahkan 12 situs PET ke jaringan Curium yang sudah...
-
此項擬議的 Eczacıbaşı-Monrol 收購將: 在現有的鑥-177 合作夥伴關係基礎上,創立領先的同位素製造商在 Curium 目前沒有業務的地區為其現有網絡增加 12 個 PET 站點為 Curium 增加 SPECT 生產能力和廣泛的物流基礎設施提高診斷和治療方案的可靠性,從而造福患者 巴黎, April 09, 2024 (GLOBE...
-
การเข้าซื้อกิจการ Eczacıbaşı-Monrol ที่เสนอจะ: ต่อยอดความร่วมมือที่มีอยู่ใน Lu-177 เพื่อสร้างผู้ผลิตไอโซโทปชั้นนำเพิ่มสถานที่ปฏิบัติงาน PET 12 แห่งไปยังเครือข่ายที่มีอยู่ของ Curium...
-
CURIUM AGREEMENT TO ACQUIRE ECZACIBAŞI-MONROL
-
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
-
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...
-
PARIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the marketing authorization application for PYLCLARI® (INN: Piflufolastat (18F) formerly...
-
Exciting news from Curium! Starting April 5, 2024, our Ioflupane I 123 Injection will be delivered Monday through Friday.
-
Curium, a global leader in nuclear medicine, announced today the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial.
-
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the...